Vimovo

Toothache, Chronic Pain, Migraine + 24 more

Treatment

18 FDA approvals

20 Active Studies for Vimovo

What is Vimovo

Naproxen

The Generic name of this drug

Treatment Summary

Esomeprazole, commonly known by its brand name Nexium, is a medication that reduces the amount of acid produced in the stomach. It is used to treat gastroesophageal reflux disease (GERD), stomach ulcers, and other conditions related to overproduction of stomach acid. It can also be prescribed in quadruple regimens to treat infections caused by the bacteria H. pylori. Esomeprazole is similar to other proton pump inhibitors (PPIs) such as omeprazole, lansoprazole, pantoprazole and rabeprazole. It works by binding

Naprosyn

is the brand name

image of different drug pills on a surface

Vimovo Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Naprosyn

Naproxen

1976

1260

Approved as Treatment by the FDA

Naproxen, otherwise known as Naprosyn, is approved by the FDA for 18 uses including Juvenile arthritis and Juvenile Idiopathic Arthritis (JIA) .

Juvenile arthritis

Used to treat Juvenile Idiopathic Arthritis (JIA) in combination with Esomeprazole

Juvenile Idiopathic Arthritis (JIA)

Used to treat Juvenile Idiopathic Arthritis (JIA) in combination with Esomeprazole

Toothache

Osteoarthritis (OA)

Used to treat Osteoarthritis (OA) in combination with Esomeprazole

Migraine

Rheumatoid Arthritis

Used to treat Rheumatoid Arthritis in combination with Esomeprazole

articular inflammation

Used to treat articular inflammation in combination with Esomeprazole

Inflammation

Used to treat articular inflammation in combination with Esomeprazole

Back

Ankylosing Spondylitis

Used to treat Ankylosing Spondylitis (AS) in combination with Esomeprazole

Dysmenorrhea

Osteoarthritis

Used to treat Osteoarthritis (OA) in combination with Esomeprazole

Headache

Back pain

Ankylosing Spondylitis (AS)

Used to treat Ankylosing Spondylitis (AS) in combination with Esomeprazole

Menstrual Distress (Dysmenorrhea)

Fever

Acute Coryza

Used to treat Acute Migraine in combination with Sumatriptan

Effectiveness

How Vimovo Affects Patients

Esomeprazole is a drug used to treat Gastroesophageal Reflux Disease (GERD), erosive esophagitis, and prevent duodenal ulcer recurrence. It works by blocking the enzyme in the stomach that produces acid. This reduces the amount of acid in the stomach, preventing symptoms of GERD and protecting the stomach from ulcers. Esomeprazole is similar to other drugs in its class, but it does not have anticholinergic or antihistamine side effects. Taking esomeprazole long-term can be associated with potential risks,

How Vimovo works in the body

Esomeprazole is used to reduce the amount of stomach acid produced. It does this by binding to proteins on the surface of cells in the stomach, called (H+, K+)-ATPase enzymes. This binding prevents the last step in the production of stomach acid and reduces both the normal and extra production that can occur due to triggers like stress or spicy foods. The binding of esomeprazole to the (H+, K+)-ATPase enzyme is permanent, so the effects can last for more than 24 hours.

When to interrupt dosage

The advisable amount of Vimovo is contingent upon the diagnosed circumstance, including Curling Ulcer, Hemorrhage and Critical Illness. The magnitude of dosage differs, as per the approach of delivery (e.g. Tablet, delayed release or Injection, powder, lyophilized, for solution - Intravenous) denoted in the table beneath.

Condition

Dosage

Administration

Acute Coryza

125.0 mg/mL, , 220.0 mg, 200.0 mg, 550.0 mg, 275.0 mg, 500.0 mg, 750.0 mg, 375.0 mg, 250.0 mg, 5.0 mg/mg, 125.0 mg, 60.0 mg, 1000.0 mg, 2.2 mg/mg, 1.0 mg/mg, 210.0 mg, 105.0 mg, 50.0 mg/mL, 25.0 mg/mL

, Suspension, Oral, Suspension - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet - Oral, Tablet, Tablet, film coated - Oral, Tablet, film coated, Kit, Kit - Topical, Topical, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule - Oral, Capsule, Tablet, coated, Tablet, coated - Oral, Kit - Oral, Rectal, Suppository, Suppository - Rectal, Tablet, extended release, Tablet, extended release - Oral, Cream - Topical, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Oral; Topical, Kit - Oral; Topical

Inflammation

125.0 mg/mL, , 220.0 mg, 200.0 mg, 550.0 mg, 275.0 mg, 500.0 mg, 750.0 mg, 375.0 mg, 250.0 mg, 5.0 mg/mg, 125.0 mg, 60.0 mg, 1000.0 mg, 2.2 mg/mg, 1.0 mg/mg, 210.0 mg, 105.0 mg, 50.0 mg/mL, 25.0 mg/mL

, Suspension, Oral, Suspension - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet - Oral, Tablet, Tablet, film coated - Oral, Tablet, film coated, Kit, Kit - Topical, Topical, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule - Oral, Capsule, Tablet, coated, Tablet, coated - Oral, Kit - Oral, Rectal, Suppository, Suppository - Rectal, Tablet, extended release, Tablet, extended release - Oral, Cream - Topical, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Oral; Topical, Kit - Oral; Topical

Collagen Diseases

125.0 mg/mL, , 220.0 mg, 200.0 mg, 550.0 mg, 275.0 mg, 500.0 mg, 750.0 mg, 375.0 mg, 250.0 mg, 5.0 mg/mg, 125.0 mg, 60.0 mg, 1000.0 mg, 2.2 mg/mg, 1.0 mg/mg, 210.0 mg, 105.0 mg, 50.0 mg/mL, 25.0 mg/mL

, Suspension, Oral, Suspension - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet - Oral, Tablet, Tablet, film coated - Oral, Tablet, film coated, Kit, Kit - Topical, Topical, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule - Oral, Capsule, Tablet, coated, Tablet, coated - Oral, Kit - Oral, Rectal, Suppository, Suppository - Rectal, Tablet, extended release, Tablet, extended release - Oral, Cream - Topical, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Oral; Topical, Kit - Oral; Topical

Migraine

125.0 mg/mL, , 220.0 mg, 200.0 mg, 550.0 mg, 275.0 mg, 500.0 mg, 750.0 mg, 375.0 mg, 250.0 mg, 5.0 mg/mg, 125.0 mg, 60.0 mg, 1000.0 mg, 2.2 mg/mg, 1.0 mg/mg, 210.0 mg, 105.0 mg, 50.0 mg/mL, 25.0 mg/mL

, Suspension, Oral, Suspension - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet - Oral, Tablet, Tablet, film coated - Oral, Tablet, film coated, Kit, Kit - Topical, Topical, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule - Oral, Capsule, Tablet, coated, Tablet, coated - Oral, Kit - Oral, Rectal, Suppository, Suppository - Rectal, Tablet, extended release, Tablet, extended release - Oral, Cream - Topical, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Oral; Topical, Kit - Oral; Topical

Migraine

125.0 mg/mL, , 220.0 mg, 200.0 mg, 550.0 mg, 275.0 mg, 500.0 mg, 750.0 mg, 375.0 mg, 250.0 mg, 5.0 mg/mg, 125.0 mg, 60.0 mg, 1000.0 mg, 2.2 mg/mg, 1.0 mg/mg, 210.0 mg, 105.0 mg, 50.0 mg/mL, 25.0 mg/mL

, Suspension, Oral, Suspension - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet - Oral, Tablet, Tablet, film coated - Oral, Tablet, film coated, Kit, Kit - Topical, Topical, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule - Oral, Capsule, Tablet, coated, Tablet, coated - Oral, Kit - Oral, Rectal, Suppository, Suppository - Rectal, Tablet, extended release, Tablet, extended release - Oral, Cream - Topical, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Oral; Topical, Kit - Oral; Topical

Sinusitis

125.0 mg/mL, , 220.0 mg, 200.0 mg, 550.0 mg, 275.0 mg, 500.0 mg, 750.0 mg, 375.0 mg, 250.0 mg, 5.0 mg/mg, 125.0 mg, 60.0 mg, 1000.0 mg, 2.2 mg/mg, 1.0 mg/mg, 210.0 mg, 105.0 mg, 50.0 mg/mL, 25.0 mg/mL

, Suspension, Oral, Suspension - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet - Oral, Tablet, Tablet, film coated - Oral, Tablet, film coated, Kit, Kit - Topical, Topical, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule - Oral, Capsule, Tablet, coated, Tablet, coated - Oral, Kit - Oral, Rectal, Suppository, Suppository - Rectal, Tablet, extended release, Tablet, extended release - Oral, Cream - Topical, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Oral; Topical, Kit - Oral; Topical

Influenza

125.0 mg/mL, , 220.0 mg, 200.0 mg, 550.0 mg, 275.0 mg, 500.0 mg, 750.0 mg, 375.0 mg, 250.0 mg, 5.0 mg/mg, 125.0 mg, 60.0 mg, 1000.0 mg, 2.2 mg/mg, 1.0 mg/mg, 210.0 mg, 105.0 mg, 50.0 mg/mL, 25.0 mg/mL

, Suspension, Oral, Suspension - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet - Oral, Tablet, Tablet, film coated - Oral, Tablet, film coated, Kit, Kit - Topical, Topical, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule - Oral, Capsule, Tablet, coated, Tablet, coated - Oral, Kit - Oral, Rectal, Suppository, Suppository - Rectal, Tablet, extended release, Tablet, extended release - Oral, Cream - Topical, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Oral; Topical, Kit - Oral; Topical

Bursitis

125.0 mg/mL, , 220.0 mg, 200.0 mg, 550.0 mg, 275.0 mg, 500.0 mg, 750.0 mg, 375.0 mg, 250.0 mg, 5.0 mg/mg, 125.0 mg, 60.0 mg, 1000.0 mg, 2.2 mg/mg, 1.0 mg/mg, 210.0 mg, 105.0 mg, 50.0 mg/mL, 25.0 mg/mL

, Suspension, Oral, Suspension - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet - Oral, Tablet, Tablet, film coated - Oral, Tablet, film coated, Kit, Kit - Topical, Topical, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule - Oral, Capsule, Tablet, coated, Tablet, coated - Oral, Kit - Oral, Rectal, Suppository, Suppository - Rectal, Tablet, extended release, Tablet, extended release - Oral, Cream - Topical, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Oral; Topical, Kit - Oral; Topical

Fever

125.0 mg/mL, , 220.0 mg, 200.0 mg, 550.0 mg, 275.0 mg, 500.0 mg, 750.0 mg, 375.0 mg, 250.0 mg, 5.0 mg/mg, 125.0 mg, 60.0 mg, 1000.0 mg, 2.2 mg/mg, 1.0 mg/mg, 210.0 mg, 105.0 mg, 50.0 mg/mL, 25.0 mg/mL

, Suspension, Oral, Suspension - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet - Oral, Tablet, Tablet, film coated - Oral, Tablet, film coated, Kit, Kit - Topical, Topical, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule - Oral, Capsule, Tablet, coated, Tablet, coated - Oral, Kit - Oral, Rectal, Suppository, Suppository - Rectal, Tablet, extended release, Tablet, extended release - Oral, Cream - Topical, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Oral; Topical, Kit - Oral; Topical

Arthritis, Juvenile

125.0 mg/mL, , 220.0 mg, 200.0 mg, 550.0 mg, 275.0 mg, 500.0 mg, 750.0 mg, 375.0 mg, 250.0 mg, 5.0 mg/mg, 125.0 mg, 60.0 mg, 1000.0 mg, 2.2 mg/mg, 1.0 mg/mg, 210.0 mg, 105.0 mg, 50.0 mg/mL, 25.0 mg/mL

, Suspension, Oral, Suspension - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet - Oral, Tablet, Tablet, film coated - Oral, Tablet, film coated, Kit, Kit - Topical, Topical, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule - Oral, Capsule, Tablet, coated, Tablet, coated - Oral, Kit - Oral, Rectal, Suppository, Suppository - Rectal, Tablet, extended release, Tablet, extended release - Oral, Cream - Topical, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Oral; Topical, Kit - Oral; Topical

Dysmenorrhea

125.0 mg/mL, , 220.0 mg, 200.0 mg, 550.0 mg, 275.0 mg, 500.0 mg, 750.0 mg, 375.0 mg, 250.0 mg, 5.0 mg/mg, 125.0 mg, 60.0 mg, 1000.0 mg, 2.2 mg/mg, 1.0 mg/mg, 210.0 mg, 105.0 mg, 50.0 mg/mL, 25.0 mg/mL

, Suspension, Oral, Suspension - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet - Oral, Tablet, Tablet, film coated - Oral, Tablet, film coated, Kit, Kit - Topical, Topical, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule - Oral, Capsule, Tablet, coated, Tablet, coated - Oral, Kit - Oral, Rectal, Suppository, Suppository - Rectal, Tablet, extended release, Tablet, extended release - Oral, Cream - Topical, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Oral; Topical, Kit - Oral; Topical

Spasm

125.0 mg/mL, , 220.0 mg, 200.0 mg, 550.0 mg, 275.0 mg, 500.0 mg, 750.0 mg, 375.0 mg, 250.0 mg, 5.0 mg/mg, 125.0 mg, 60.0 mg, 1000.0 mg, 2.2 mg/mg, 1.0 mg/mg, 210.0 mg, 105.0 mg, 50.0 mg/mL, 25.0 mg/mL

, Suspension, Oral, Suspension - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet - Oral, Tablet, Tablet, film coated - Oral, Tablet, film coated, Kit, Kit - Topical, Topical, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule - Oral, Capsule, Tablet, coated, Tablet, coated - Oral, Kit - Oral, Rectal, Suppository, Suppository - Rectal, Tablet, extended release, Tablet, extended release - Oral, Cream - Topical, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Oral; Topical, Kit - Oral; Topical

Epilepsy, Post-Traumatic

125.0 mg/mL, , 220.0 mg, 200.0 mg, 550.0 mg, 275.0 mg, 500.0 mg, 750.0 mg, 375.0 mg, 250.0 mg, 5.0 mg/mg, 125.0 mg, 60.0 mg, 1000.0 mg, 2.2 mg/mg, 1.0 mg/mg, 210.0 mg, 105.0 mg, 50.0 mg/mL, 25.0 mg/mL

, Suspension, Oral, Suspension - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet - Oral, Tablet, Tablet, film coated - Oral, Tablet, film coated, Kit, Kit - Topical, Topical, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule - Oral, Capsule, Tablet, coated, Tablet, coated - Oral, Kit - Oral, Rectal, Suppository, Suppository - Rectal, Tablet, extended release, Tablet, extended release - Oral, Cream - Topical, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Oral; Topical, Kit - Oral; Topical

Back

125.0 mg/mL, , 220.0 mg, 200.0 mg, 550.0 mg, 275.0 mg, 500.0 mg, 750.0 mg, 375.0 mg, 250.0 mg, 5.0 mg/mg, 125.0 mg, 60.0 mg, 1000.0 mg, 2.2 mg/mg, 1.0 mg/mg, 210.0 mg, 105.0 mg, 50.0 mg/mL, 25.0 mg/mL

, Suspension, Oral, Suspension - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet - Oral, Tablet, Tablet, film coated - Oral, Tablet, film coated, Kit, Kit - Topical, Topical, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule - Oral, Capsule, Tablet, coated, Tablet, coated - Oral, Kit - Oral, Rectal, Suppository, Suppository - Rectal, Tablet, extended release, Tablet, extended release - Oral, Cream - Topical, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Oral; Topical, Kit - Oral; Topical

Primary Dysmenorrhoea

125.0 mg/mL, , 220.0 mg, 200.0 mg, 550.0 mg, 275.0 mg, 500.0 mg, 750.0 mg, 375.0 mg, 250.0 mg, 5.0 mg/mg, 125.0 mg, 60.0 mg, 1000.0 mg, 2.2 mg/mg, 1.0 mg/mg, 210.0 mg, 105.0 mg, 50.0 mg/mL, 25.0 mg/mL

, Suspension, Oral, Suspension - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet - Oral, Tablet, Tablet, film coated - Oral, Tablet, film coated, Kit, Kit - Topical, Topical, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule - Oral, Capsule, Tablet, coated, Tablet, coated - Oral, Kit - Oral, Rectal, Suppository, Suppository - Rectal, Tablet, extended release, Tablet, extended release - Oral, Cream - Topical, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Oral; Topical, Kit - Oral; Topical

Tendinopathy

125.0 mg/mL, , 220.0 mg, 200.0 mg, 550.0 mg, 275.0 mg, 500.0 mg, 750.0 mg, 375.0 mg, 250.0 mg, 5.0 mg/mg, 125.0 mg, 60.0 mg, 1000.0 mg, 2.2 mg/mg, 1.0 mg/mg, 210.0 mg, 105.0 mg, 50.0 mg/mL, 25.0 mg/mL

, Suspension, Oral, Suspension - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet - Oral, Tablet, Tablet, film coated - Oral, Tablet, film coated, Kit, Kit - Topical, Topical, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule - Oral, Capsule, Tablet, coated, Tablet, coated - Oral, Kit - Oral, Rectal, Suppository, Suppository - Rectal, Tablet, extended release, Tablet, extended release - Oral, Cream - Topical, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Oral; Topical, Kit - Oral; Topical

Arthritis, Gouty

125.0 mg/mL, , 220.0 mg, 200.0 mg, 550.0 mg, 275.0 mg, 500.0 mg, 750.0 mg, 375.0 mg, 250.0 mg, 5.0 mg/mg, 125.0 mg, 60.0 mg, 1000.0 mg, 2.2 mg/mg, 1.0 mg/mg, 210.0 mg, 105.0 mg, 50.0 mg/mL, 25.0 mg/mL

, Suspension, Oral, Suspension - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet - Oral, Tablet, Tablet, film coated - Oral, Tablet, film coated, Kit, Kit - Topical, Topical, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule - Oral, Capsule, Tablet, coated, Tablet, coated - Oral, Kit - Oral, Rectal, Suppository, Suppository - Rectal, Tablet, extended release, Tablet, extended release - Oral, Cream - Topical, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Oral; Topical, Kit - Oral; Topical

Rheumatoid Arthritis

125.0 mg/mL, , 220.0 mg, 200.0 mg, 550.0 mg, 275.0 mg, 500.0 mg, 750.0 mg, 375.0 mg, 250.0 mg, 5.0 mg/mg, 125.0 mg, 60.0 mg, 1000.0 mg, 2.2 mg/mg, 1.0 mg/mg, 210.0 mg, 105.0 mg, 50.0 mg/mL, 25.0 mg/mL

, Suspension, Oral, Suspension - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet - Oral, Tablet, Tablet, film coated - Oral, Tablet, film coated, Kit, Kit - Topical, Topical, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule - Oral, Capsule, Tablet, coated, Tablet, coated - Oral, Kit - Oral, Rectal, Suppository, Suppository - Rectal, Tablet, extended release, Tablet, extended release - Oral, Cream - Topical, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Oral; Topical, Kit - Oral; Topical

Hay Fever

125.0 mg/mL, , 220.0 mg, 200.0 mg, 550.0 mg, 275.0 mg, 500.0 mg, 750.0 mg, 375.0 mg, 250.0 mg, 5.0 mg/mg, 125.0 mg, 60.0 mg, 1000.0 mg, 2.2 mg/mg, 1.0 mg/mg, 210.0 mg, 105.0 mg, 50.0 mg/mL, 25.0 mg/mL

, Suspension, Oral, Suspension - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet - Oral, Tablet, Tablet, film coated - Oral, Tablet, film coated, Kit, Kit - Topical, Topical, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule - Oral, Capsule, Tablet, coated, Tablet, coated - Oral, Kit - Oral, Rectal, Suppository, Suppository - Rectal, Tablet, extended release, Tablet, extended release - Oral, Cream - Topical, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Oral; Topical, Kit - Oral; Topical

Nasal Congestion

125.0 mg/mL, , 220.0 mg, 200.0 mg, 550.0 mg, 275.0 mg, 500.0 mg, 750.0 mg, 375.0 mg, 250.0 mg, 5.0 mg/mg, 125.0 mg, 60.0 mg, 1000.0 mg, 2.2 mg/mg, 1.0 mg/mg, 210.0 mg, 105.0 mg, 50.0 mg/mL, 25.0 mg/mL

, Suspension, Oral, Suspension - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet - Oral, Tablet, Tablet, film coated - Oral, Tablet, film coated, Kit, Kit - Topical, Topical, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule - Oral, Capsule, Tablet, coated, Tablet, coated - Oral, Kit - Oral, Rectal, Suppository, Suppository - Rectal, Tablet, extended release, Tablet, extended release - Oral, Cream - Topical, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Oral; Topical, Kit - Oral; Topical

Warnings

Vimovo Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Naproxen may interact with Pulse Frequency

Coronary Artery Bypass Grafting

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Naproxen may interact with Pulse Frequency

Severe Hypersensitivity Reactions

Do Not Combine

Naproxen may interact with Pulse Frequency

There are 20 known major drug interactions with Vimovo.

Common Vimovo Drug Interactions

Drug Name

Risk Level

Description

Amiodarone

Major

The metabolism of Amiodarone can be decreased when combined with Naproxen.

Brigatinib

Major

The metabolism of Brigatinib can be decreased when combined with Naproxen.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Naproxen.

Enasidenib

Major

The metabolism of Enasidenib can be decreased when combined with Naproxen.

Erlotinib

Major

The metabolism of Erlotinib can be decreased when combined with Naproxen.

Vimovo Toxicity & Overdose Risk

Common side effects of overdoses on this drug include blurry vision, confusion, tiredness, dry mouth, feeling flushed, headaches, nausea, a rapid heartbeat, and sweating.

image of a doctor in a lab doing drug, clinical research

Vimovo Novel Uses: Which Conditions Have a Clinical Trial Featuring Vimovo?

26 active clinical trials are currently assessing the utility of Vimovo in addressing previous gastric or duodenal ulcer, Stomach Ulcer and Peptic Ulcer.

Condition

Clinical Trials

Trial Phases

Influenza

29 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Phase 1, Phase 3

Postoperative Pain

19 Actively Recruiting

Phase 4, Phase 2, Phase 1, Phase 3, Not Applicable

Chronic Pain

130 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Phase 3, Early Phase 1, Phase 1

Inflammation

0 Actively Recruiting

Bursitis

0 Actively Recruiting

Tendinopathy

0 Actively Recruiting

Nasal Congestion

0 Actively Recruiting

Juvenile arthritis

8 Actively Recruiting

Phase 2, Not Applicable, Phase 3

Rheumatoid Arthritis

55 Actively Recruiting

Not Applicable, Phase 4, Phase 3, Phase 2, Phase 1

Spasm

0 Actively Recruiting

Back

8 Actively Recruiting

Not Applicable, Phase 3, Early Phase 1, Phase 1

Fever

2 Actively Recruiting

Not Applicable, Phase 4

Collagen Diseases

0 Actively Recruiting

Osteoarthritis

0 Actively Recruiting

Migraine

13 Actively Recruiting

Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4

Arthritis, Juvenile

1 Actively Recruiting

Not Applicable

Migraine

51 Actively Recruiting

Phase 4, Not Applicable, Phase 1, Phase 3, Phase 2, Early Phase 1

Arthritis, Gouty

0 Actively Recruiting

Acute Coryza

0 Actively Recruiting

Epilepsy, Post-Traumatic

0 Actively Recruiting

Vimovo Reviews: What are patients saying about Vimovo?

5

Patient Review

12/29/2019

Vimovo for Osteoarthritis and High Risk of Developing Gastric Ulcers

I don't understand why people are so uneducated about their medications. Naprosyn Sodium is the same drug as Alleve, and the side effects come from IT. The other drug is simply to try to reduce the harsh effects of Naprosyn Sodium on your G I tract. It's not a separate medication, but a combination of two drugs.

5

Patient Review

10/4/2016

Vimovo for Osteoarthritis and High Risk of Developing Gastric Ulcers

I've been taking this treatment for around a week to help with my hip pain. While it does work well, I have noticed some concerning side effects like dizziness and heart palpitations. Not sure if I'll be able to take it long-term.

4

Patient Review

11/2/2016

Vimovo for Osteoarthritis and High Risk of Developing Gastric Ulcers

Vimovo has done wonders for my arthritis pain. I was previously taking four Aleve pills per day, plus four Nexium pills (all over the counter at the recommended dosage), but now I only need to take two Vimovo pills and I'm good to go. No more stomach burn or nausea, and a lot fewer pills!

3.7

Patient Review

4/17/2018

Vimovo for Osteoarthritis and High Risk of Developing Gastric Ulcers

I started taking Vimovo because I developed ulcers from Naproxin. I was on it for over a year, and only realized how much it impacted my mood once I stopped taking it. It did help with my Fibro pain and back issues, but the cost was too high.

3.7

Patient Review

3/20/2019

Vimovo for Osteoarthritis and High Risk of Developing Gastric Ulcers

Worked well until an unfortunate side effect developed.

3

Patient Review

10/16/2015

Vimovo for Rheumatoid Arthritis and High Risk of Developing Gastric Ulcers

I was prescribed this for an infection in my jaw that caused it to click when I opened my mouth. After four days of taking the medication as directed, I experienced extreme drowsiness, muscle pain, headaches, and neck pain. I also had trouble eating and felt nauseous most of the time. This was by far the worst experience I've ever had with a medication and would not recommend it to anyone.

2.3

Patient Review

5/7/2018

Vimovo for Osteoarthritis and High Risk of Developing Gastric Ulcers

I've been struggling with Achilles tendinitis for over half a year now and have tried many different treatments to no avail. My doctor prescribed Vimovo, but after taking it I experienced severe pain in my abdomen and was unable to sleep. I'll be discontinuing use of this medication and instead stick to Advil and Turmeric.

2.3

Patient Review

4/9/2019

Vimovo for Osteoarthritis and High Risk of Developing Gastric Ulcers

Unfortunately, this treatment gave me really severe diarrhea and stomach pain. It also killed my appetite. I had to stop taking it after a month.

2

Patient Review

9/24/2015

Vimovo for Ankylosing Spondylitis and High Risk of Developing Gastric Ulcers

2

Patient Review

1/21/2020

Vimovo for Rheumatoid Arthritis and High Risk of Developing Gastric Ulcers

I was prescribed this medication to help with my rheumatoid arthritis. Unfortunately, I saw zero difference after taking it as directed; might as well have eaten Smarties.

1

Patient Review

8/28/2017

Vimovo for Rheumatoid Arthritis and High Risk of Developing Gastric Ulcers

I had such terrible reactions to this medicine- vomiting, diarrhea, and numbness in my extremities. I think it might have also been causing problems with my liver or gallbladder because I was vomiting green bile.

1

Patient Review

5/12/2019

Vimovo for Osteoarthritis and High Risk of Developing Gastric Ulcers

While this medication did help my arthritis pain, it also caused severe and permanent damage to the lining of my stomach after just six months. I had to be hospitalized as a result and was diagnosed with chronic microscopic colitis. If there were any way to take legal action against the manufacturer of this drug, I would.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about vimovo

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

When should I take vimovo?

"Vimovo is typically taken twice per day, at least 30 minutes before a meal. Follow directions on the prescription label and read all medication guides or instruction sheets. Use the medicine as directed. Swallow the tablet whole and do not crush, chew, or break it."

Answered by AI

Is vimovo the same as ibuprofen?

"The drugs Vimovo and Ibuprofen both contain NSAIDs. Vimovo also contains a proton pump inhibitor. There are various brand names for ibuprofen, such as Advil and Motrin. Motrin (Ibuprofen) can be bought OTC or as a generic."

Answered by AI

What is vimovo pills used for?

"This medication falls under the NSAID category and is used to treat various forms of arthritis. The active ingredients in this medication are esomeprazole and naproxen. This medication carries a high risk for stomach bleeding and ulcers, and should be used with caution in patients with a history of gastric ulcers."

Answered by AI

Is vimovo a painkiller?

"Esomeprazole is a medicine that reduces the amount of acid produced in your stomach.

If you are suffering from pain and need an anti-inflammatory painkiller, Vimovo may be a good option for you as it also provides stomach protection. Vimovo 500mg/20mg modified release tablets contain naproxen and esomeprazole as active ingredients. Naproxen is a powerful anti-inflammatory painkiller (also known as an NSAID) that can be used to treat various painful conditions. Esomeprazole is a medicine designed to reduce the amount of acid produced in your stomach."

Answered by AI

Clinical Trials for Vimovo

Image of University Center for Ambulatory Surgery in Somerset, United States.

Infusion Pump for Postoperative Pain

18+
All Sexes
Somerset, NJ

This study will be a pragmatic, prospective cluster randomized trial, where clusters will formed based on sequential 2 week time increments across the study recruitment period.. Patients 18 years or older undergoing ACL reconstruction, open shoulder labrum or rotator cuff surgery, arthroscopic rotator cuff repair, proximal or distal patellar realignment surgery, open knee arthrotomy cases (i.e. inside out meniscus repair, osteochondral allograft transplantation (OCA), meniscal allograft transplantation (MAT)) at University Center for Ambulatory Surgery, LLC (UOA) will be reviewed for eligibility. Once identified, potential study subjects will be asked whether they are interested in participating in the project. If the patient agrees, the subject will be given the informed consent to read and sign. Objectives: The primary objective is to compare the effectiveness of postoperative infusion pain pump versus preoperative nerve block in reducing visual analog pain scores/numerical pain rating scale (VAS/NPRS) in the postoperative period. The second objective is to evaluate the requirement of narcotic and non-narcotic analgesic medications between the two groups. Hypotheses: Use of continuous infusion pain pump or single shot peripheral block will result in similar post-operative pain control after outpatient sports medicine surgical cases.

Phase 4
Recruiting

University Center for Ambulatory Surgery

Image of University of North Carolina at Chapel Hill in Chapel Hill, United States.

Pain Medicines for Period Pain in Crohn's Disease

18 - 44
Female
Chapel Hill, NC

The purpose of this pilot study is to prepare for a larger study that will compare the effectiveness and safety of two common pain medications, ibuprofen and acetaminophen, to help treat period cramps in women with Crohn's disease. The goal of this study is to identify any challenges in running a larger study. The investigators will track how many people sign up for the study, how well participants follow the study plan, how many people stay in the study, and whether they are able to complete all the study activities, such as taking the medication, submitting samples, and filling out surveys. During the study, participants will undergo a screening visit that includes a blood draw, physical exam, pregnancy test, stool testing, and complete surveys about Crohn's disease and menstrual cycles. Once this visit is complete, the rest of the study will occur at home. Participants will be assigned to take either ibuprofen or acetaminophen to help treat period cramps for four menstrual cycles in a row. Participants will take ibuprofen for two cycles and acetaminophen for two cycles. Participants will know which medication is being taken at any given time, but the order in which they take the medications will be randomly assigned. Before each menstrual cycle, participants will submit a stool sample and fill out a short (\<1 minute) electronic survey. When participants develop period cramps, they will take the assigned medication for three days and fill out short (\<1 minute) electronic surveys about their cramps. After participants finish taking the medication for three days, they will submit another stool sample and fill out two more short (\<1 minute) electronic surveys. After have completing this process for four menstrual cycles, a remote interview with a researcher to give feedback on the study will be conducted.

Waitlist Available
Has No Placebo

University of North Carolina at Chapel Hill

Erica J Brenner, MD, MSCR

Image of AltaSciences, Inc in Cypress, United States.

SBS-147 Safety Study

18 - 55
All Sexes
Cypress, CA

This study is part of the HEAL Initiative supported by the NIH. The purpose of this study is to learn how safe the study drug, SBS-147, is and how people's bodies respond to and process it. Researchers will also look for any side effects that may occur when taking SBS-147. Some participants will receive SBS-147, and others will receive a placebo, which looks the same but does not contain any medicine. This helps researchers fairly compare results. The study includes two parts: Single-Dose Group, where Participants receive SBS-147 or placebo one time. Multiple-Dose Group, where Participants receive SBS-147 or placebo once or twice daily for 7 days.

Phase 1
Waitlist Available

AltaSciences, Inc

Jeff Reich, MD

Sparian Biosciences, Inc

Have you considered Vimovo clinical trials?

We made a collection of clinical trials featuring Vimovo, we think they might fit your search criteria.
Go to Trials

Have you considered Vimovo clinical trials?

We made a collection of clinical trials featuring Vimovo, we think they might fit your search criteria.
Go to Trials

Have you considered Vimovo clinical trials?

We made a collection of clinical trials featuring Vimovo, we think they might fit your search criteria.
Go to Trials